Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697307 | 0.94 | SYK (0.32) | — | |
| SCHEMBL4697306 | 0.83 | KDM4E (0.35) | ATR | |
| SCHEMBL4697332 | 0.81 | SYK (0.34) | — | |
| SCHEMBL4696451 | 0.72 | SYK (0.38) | MAPKAPK2 | |
| SCHEMBL22485954 | 0.67 | CYP11B2 (0.33) | — | |
| SCHEMBL10618564 | 0.66 | KDM4E (0.43) | ATR | |
| SCHEMBL7532545 | 0.66 | CUL4A (0.37) | — | |
| SCHEMBL25263548 | 0.65 | GPR119 (0.41) | — | |
| SCHEMBL31349701 | 0.65 | USP30 (0.32) | — | |
| SCHEMBL506789 | 0.65 | USP30 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1351959-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002030929-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | MAPKAPK2 1682/4885ATR 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.